Devirex patent approved in the EU

2013-10-20 12:00

A Devirex AG patent has now been granted by the European Patent Office for the whole EU. On completion of a successful clinical study at the University of Zurich in which it has demonstrated that a previously completely unknown effect of the components of lipivir®. The management team at Devirex immediately filed a patent at the European Patent Office for later filing in all relevant geographies in the world.

The approval of this patent means that polyethylene glycols for the prevention of Herpes Simplex diseases (cold sores, genital herpes, herpes Zoster) is protected as Intellectual Property of Devirex AG in all European countries.

Devirex’ portfolio of patents comprise a broad range of formulations of different polyethylene glycols for the prevention of all herpes diseases.

“This is tremendous news for us as we now can start marketing our fantastic product in Europe” commented Devirex CEO Dr Peter Vitins.

Back to news